Immunotherapy is one of the most promising areas of cancer research. Drugs like checkpoint inhibitors, monoclonal and bispecific anitbodies, antibody drug conjugates and CAR-T cell therapy are all extensively being studied in AML.

Join us live on May 26th at 11 AM EST to learn from Dr. Joseph Jurcic, an AML expert from the Herbert Irving Comprehensive Cancer Center at Columbia University, about an exciting new immunotherapy drug in development called magrolimab which is a monoclonal antibody against CD47 and macrophage checkpoint inhibitor.

During the show, Dr. Jurcic will discuss what magrolimab is, how it is helping AML patients and two upcoming trials he will be participating in that will use magrolimab in combination with other AML drugs. Learn all about the immune system and this emerging therapy with a unique opportunity to directly ask Dr. Jurcic your questions!

Thank you to our episode sponsor, Abbvie.

HealthTree Podcast for AML: Dr. Joseph Jurcic, Columbia University

Share

Embed